SCHEMBL10027234

SCHEMBL10027234

CCCCc1cnc2c(O)cccn2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MPI P34949 1/20 0.39
▸ ELANE P08246 1/20 0.38
▸ CTSG P08311 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ BID P55957 3/20 0.36
▸ MCL1 Q07820 3/20 0.36
▸ BCL2L1 Q07817 2/20 0.36
▸ BAK1 Q16611 2/20 0.36
▸ KAT8 Q9H7Z6 2/20 0.36
▸ PPARG P37231 1/20 0.36
▸ PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10027188 0.92 LMNA (0.40) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL10027225 0.87 LMNA (0.43) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL15624348 0.85 TP53 (0.47) MAPTALDH1A1KDM4ELMNAGAA
SCHEMBL10027236 0.84 MAPT (0.38) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL17808853 0.83 KDM4E (0.39) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL13313513 0.80 KDM4E (0.39) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL23696295 0.80 LMNA (0.40) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL17802289 0.80 KDM4E (0.40) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL17808887 0.80 CHEK1 (0.40) MAPTALDH1A1KDM4ELMNAGLA
SCHEMBL10027235 0.79 MAPT (0.36) MAPTALDH1A1KDM4ELMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163018-B2 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (AU) 2015-10-20 — — US disclosed
US-9163018-B2 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (AU) 2015-10-20 — — US disclosed
US-20140088122-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2014-03-27 — — US disclosed
US-20140088122-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2014-03-27 — — US disclosed
EP-2012789-B1 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY LTD (AU) 2013-09-25 — — EP disclosed
EP-2514423-A2 Method of treatment of age-related macular degeneration (AMD) Prana Biotechnology Ltd (AU) 2012-10-24 — — EP disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2011-03-24 — — US disclosed
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2011-03-24 — — US disclosed
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-10 — — US disclosed
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-10 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
WO-2007147217-A1 METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR PRANA BIOTECHNOLOGY LIMITED (AU) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 MAPT 1067/4885ALDH1A1 1278/4885KDM4E 2823/4885
US-20140088122-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C MAPT 2308/4885ALDH1A1 238/4885KDM4E 4624/4885
US-20100144693-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C MAPT 2308/4885ALDH1A1 238/4885KDM4E 4624/4885
US-20110071167-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) ALDH1A2, AGER, PDE6C MAPT 2308/4885ALDH1A1 238/4885KDM4E 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback